litlas
Log inCreate account

Antonio González-Martı́n

Active 2005–2025

126
Papers
29,359
Citations
60
h-index
113
i10-index

Citations

Citations per year for Antonio González-Martı́n1994: 2 citations1999: 1 citations2006: 2 citations2007: 3 citations2008: 1 citations2009: 2 citations2010: 6 citations2011: 3 citations2012: 14 citations2013: 15 citations2014: 26 citations2015: 25 citations2016: 70 citations2017: 116 citations2018: 128 citations2019: 804 citations2020: 1,358 citations2021: 1,539 citations2022: 1,475 citations2023: 1,309 citations2024: 2,228 citations2025: 1,083 citations2026: 21 citations1995–1998: no citations, so these years are not shown2000–2005: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,256 citing papers, 18.7% of this breakdownChina: 1,312 citing papers, 10.9% of this breakdownItaly: 1,051 citing papers, 8.7% of this breakdownUnited Kingdom: 795 citing papers, 6.6% of this breakdownFrance: 635 citing papers, 5.3% of this breakdownSpain: 575 citing papers, 4.8% of this breakdownGermany: 519 citing papers, 4.3% of this breakdownCanada: 468 citing papers, 3.9% of this breakdownJapan: 364 citing papers, 3% of this breakdownNetherlands: 295 citing papers, 2.4% of this breakdownAustralia: 288 citing papers, 2.4% of this breakdownSwitzerland: 288 citing papers, 2.4% of this breakdown
0%18.7%Other 26.6%

Institutions

Fields

  • Medicine77.1%
  • Biochemistry, Genetics and Molecular Biology17.6%
  • Immunology and Microbiology3%
  • Materials Science0.5%
  • Computer Science0.4%
  • Engineering0.2%
  • Other1.2%

Topics

  • Ovarian cancer diagnosis and treatment10.3%
  • PARP inhibition in cancer therapy9.3%
  • Endometrial and Cervical Cancer Treatments6.7%
  • HER2/EGFR in Cancer Research4.4%
  • Cancer Immunotherapy and Biomarkers3.1%
  • Advanced Breast Cancer Therapies2.9%
  • Other63.3%

Coauthors

All papers

Open in search
  1. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

    Authors: Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, Do‐Youn Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Anitra Fielding, Yan Ma, Soham D. Puvvada, Norah J. Shire, Jung‐Yun Lee - Journal of Clinical Oncology 2023 cited by 931

  2. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Authors: Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro - New England Journal of Medicine 2018 cited by 2,839

  3. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Authors: Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, René dePont Christensen, Whitney A. Spannuth Graybill, Mansoor R. Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, К. Jardon, Andrés Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O’Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley Haggerty, María Jesús Rubio-Pérez, Mark S. Shahin, Giorgia Mangili, William H. Bradley, Ilan Bruchim, Kaiming Sun, Izabela A. Malinowska, Yong Li, Divya Gupta, Bradley J. Monk - New England Journal of Medicine 2019 cited by 2,262

  4. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

    Authors: Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martı́n, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédèric Selle, Jalid Sehouli, Domenica Lorusso, Eva María Guerra Alia, Alexander Reinthaller, Shoji Nagao, Claudia Lefeuvre‐Plesse, Ulrich Canzler, Giovanni Scambia, Alain Lortholary, Frederik Marmé, Pierre Combe, Nikolaus de Gregorio, Manuel Rodrigues, Paul Buderath, Coraline Dubot, Alexander Burges, Benoît You, Éric Pujade-Lauraine, Philipp Harter - New England Journal of Medicine 2019 cited by 2,040

  5. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma

    Authors: Nicole Concin, Xavier Matías‐Guiu, Ignace Vergote, David Cibula, Mansoor Raza Mirza, Simone Marnitz, Jonathan A. Ledermann, Tjalling Bosse, Cyrus Chargari, Anna Fagotti, Christina Fotopoulou, Antonio González-Martı́n, Sigurd Lax, Domenica Lorusso, Christian Marth, Philippe Morice, Remi A. Nout, D. O’Donnell, Denis Querleu, Maria Rosaria Raspollini, Jalid Sehouli, Alina Sturdza, Alexandra Taylor, Anneke M. Westermann, Pauline Wimberger, Nicoletta Colombo, François Planchamp, Carien L. Creutzberg - Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin 2020 cited by 1,933

  6. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

    Authors: Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa Ben-Baruch, Christian Marth, Radosław Mądry, René dePont Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas du Bois, Antonio González-Martı́n, Philippe Follana, Benedict B. Benigno, Per Rosenberg, Lucy Gilbert, B.J. Rimel, Joseph Buscema, John Balser, Shefali Agarwal, Ursula A. Matulonis - New England Journal of Medicine 2016 cited by 2,458

  7. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    Authors: Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin, Alla Lisyanskaya, Sandro Pignata, Ignace Vergote, Francesco Raspagliesi, Gabe S. Sonke, Michael J. Birrer, Diane Provencher, Jalid Sehouli, Nicoletta Colombo, Antonio González-Martı́n, Ana Oaknin, Petronella B. Ottevanger, Vilius Rudaitis, Kianoosh Katchar, Huita Wu, Stephen J. O’Keefe, Jane Ruman, Jonathan A. Ledermann - Annals of Oncology 2019 cited by 840

  8. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Authors: Sandra M. Swain, David Miles, Sung‐Bae Kim, Young‐Hyuck Im, Seock‐Ah Im, Semiglazov Vf, Eva Ciruelos, Andreas Schneeweiß, Sherene Loi, Estefanía Monturus, Emma Clark, Adam Knott, Eleonora Restuccia, Mark Benyunes, Javier Cortés, Richy Agajanian, Rizvana Ahmad, Bahriye Aktas, Victor Hugo Medeiros Alencar, Dino Amadori, Jurandyr Moreira de Andrade, Fábio Franke, Catia Angiolini, Kenjiro Aogi, Jess F. Armor, Wichit Arpornwirat, L. Assersohn, William Audeh, Walter E. Aulitzky, Sérgio Jobim Azevedo, Maria Alejandra Bartoli, Norberto Batista López, María Inés Bianconi, Laura Biganzoli, Ruemu Birhiray, Marianna Bitiņa, Ron Blachy, Kimberly Blackwell, Rita A. Blanchard, Paulette Blanchet, Ion Boiangiu, B. Bower, Christine Brezden‐Masley, Adam Brufsky, Leanne S. Budde, Priscilla B. Caguioa, Lourdes Calvo, Mario Campone, Robert R. Carroll, Hugo R. Castro, Valorie F. Chan, Veena Charu, Saverio Cinieri, Michael Clemens, Emilio Alba Conejo, Eduardo Côrtes, Bruno Coudert, Eduardo Cronemberger, Daniel de Iracema Gomes Cubero, Shaker R. Dakhil, Brooke Daniel, Neville Davidson, Maria de Fátima Dias Gauí, Susana de la Cruz, María del Pilar, G. Delgado, John Ellerton, César Estuardo, Louis Fehrenbacher, Jean-­Marc Ferrero, Patrick J. Flynn, Małgorzata Foszczyńska‐Kłoda, Sandra Franco, Hirofumi Fujii, Chris Gallagher, Teresa Gamucci, N Giacomi, Miguel Gil Gil, Antonio González-Martı́n, Vera Gorbunova, E. Gotovkin, Nathan Green, Elza Grincuka, Eva‐Maria Grischke, Vincent Hansen, Jeffrey B. Hargis, Maik Hauschild, Roberto Hegg, Carolyn B. Hendricks, Róbert Hermann, Paulo M. Hoff, Jun Horiguchi, Javier Hornedo Muguiro, Stefano Iacobelli, Kenichi Inoue, Gustavo Ismael, Yoshinori Itoh, Dr Hiroji Iwata, D Jendiroba, Rosa Jochim and 122 more - The Lancet Oncology 2020 cited by 898

  9. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

    Authors: Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, John McNamara, Elizabeth Lowe, Mei-Lin Ah-See, Kathleen N. Moore, on behalf of the SOLO1 Investigators - Journal of Clinical Oncology 2022 cited by 475

  10. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

    Authors: Nicoletta Colombo, Cristiana Sessa, Andreas du Bois, Jonathan A. Ledermann, W. Glenn McCluggage, Iain A. McNeish, Philippe Morice, Sandro Pignata, Isabelle Ray‐Coquard, Ignace Vergote, Thaïs Baert, I. Belaroussi, A. Dashora, Siel Olbrecht, François Planchamp, Denis Querleu, Thaïs Baert, Susana Banerjee, I. Belaroussi, Paweł Blecharz, Ilan Bruchim, David Cibula, Nicoletta Colombo, Nicole Concin, Ben Davidson, A. Dashora, Mojgan Devouassoux‐Shisheboran, Andreas du Bois, Annamaria Ferrero, Rosalind Glasspool, Antonio González-Martı́n, Viola Heinzelmann‐Schwarz, Florence Joly, J.W. Kim, Frédéric Kridelka, Jonathan A. Ledermann, Domenica Lorusso, Sven� Mahner, W. Glenn McCluggage, Iain A. McNeish, Mikio Mikami, Mansoor Raza Mirza, Philippe Morice, Shibani Nicum, Siel Olbrecht, Dearbhaile M. O’Donnell, Patricia Pautier, François Planchamp, Sandro Pignata, Denis Querleu, Isabelle Ray‐Coquard, Alexandros Rodolakis, Jalid Sehouli, Fatih Selçukbırıcık, Cristiana Sessa, Nilanchali Singh, David S.P. Tan, D. Timmerman, Germana Tognon, Jacobus van der Velden, Ignace Vergote, Petronella O. Witteveen, Alain G. Zeimet - Annals of Oncology 2019 cited by 1,165

  11. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    Authors: Antonio González-Martı́n, Philipp Harter, Alexandra Léary, Domenica Lorusso, Rowan Miller, Bhavana Pothuri, Isabelle Ray‐Coquard, David S.P. Tan, E. Bellet, Ana Oaknin, Jonathan A. Ledermann - Annals of Oncology 2023 cited by 388

  12. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    Authors: Robert L. Coleman, Domenica Lorusso, Christine Gennigens, Antonio González-Martı́n, Leslie M. Randall, David Cibula, Bente Lund, Linn Woelber, Sandro Pignata, Frédéric Forget, Andrés Redondo, Signe Diness Vindeløv, Menghui Chen, Jeffrey R. Harris, Margaret S. Smith, Leonardo Nicacio, Melinda Siew Leng Teng, Annouschka Laenen, Reshma Rangwala, Luís Manso, Mansoor Raza Mirza, Bradley J. Monk, Ignace Vergote, Francesco Raspagliesi, Bohuslav Melichar, Lydia Gaba Garcia, Amanda Jackson, Stéphanie Henry, Zdeněk Král, Philipp Harter, Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia - The Lancet Oncology 2021 cited by 394

  13. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial

    Authors: I. Ray-Coquard, Alexandra Léary, Sandro Pignata, Claire Cropet, Antonio González-Martı́n, Christian Marth, Shoji Nagao, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédèric Selle, Jalid Sehouli, Domenica Lorusso, Eva María Guerra Alia, Gerhard Bogner, Hiroyuki Yoshida, C. Lefeuvre-Plesse, Paul Buderath, Anna Maria Mosconi, A. Lortholary, Alexander Burges, J. Medioni, Ayşe Balat, Manuel Rodrigues, Tjoung‐Won Park‐Simon, Coraline Dubot, Dominik Denschlag, Benoît You, Éric Pujade-Lauraine, Philipp Harter - Annals of Oncology 2023 cited by 339

  14. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

    Authors: Nicoletta Colombo, Carien L. Creutzberg, Frédéric Amant, Tjalling Bosse, Antonio González-Martı́n, Jonathan A. Ledermann, Christian Marth, Remi A. Nout, Denis Querleu, Mansoor Raza Mirza, Cristiana Sessa, Miguel Abal, Özden Altundağ, Frédéric Amant, Antoni Van Leeuwenhoek, Susana Banerjee, Tjalling Bosse, Antonio Casado, L Chiva de Agustín, David Cibula, Nicoletta Colombo, Carien L. Creutzberg, José María Del Campo, Günter Emons, Frédéric Goffin, Antonio González-Martı́n, Stefano Greggi, Christine Haie-Méder, Dionyssios Katsaros, Vesna Kesić, Christian Kurzeder, Sigurd Lax, Fabrice Lécuru, Jonathan A. Ledermann, Tally Levy, Domenica Lorusso, Johanna Mäenpää, Christian Marth, Xavier Matías‐Guiu, Philippe Morice, Hans W. Nijman, Remi A. Nout, Melanie Powell, Denis Querleu, Mansoor Raza Mirza, Nicholas Reed, Alexandros Rodolakis, Helga B. Salvesen, Jalid Sehouli, Cristiana Sessa, Alexandra Taylor, Anneke M. Westermann, Alain G. Zeimet - Annals of Oncology 2015 cited by 1,380

  15. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Authors: Jonathan A. Ledermann, F. Raja, Christina Fotopoulou, Antonio González-Martı́n, Nicoletta Colombo, Cristiana Sessa - Annals of Oncology 2013 cited by 1,115

  16. ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease

    Authors: Jonathan A. Ledermann, Xavier Matías‐Guiu, Frédéric Amant, Nicole Concin, Ben Davidson, Christina Fotopoulou, Antonio González-Martı́n, Charlie Gourley, Alexandra Léary, Domenica Lorusso, Susana Banerjee, Luis Chiva, David Cibula, Nicoletta Colombo, Sabrina Croce, Ane Gerda Zahl Eriksson, Claire Falandry, D. Fischerová, Philipp Harter, Florence Joly, Conxi Lázaro, C.A.R. Lok, Sven� Mahner, Frederik Marmé, Christian Marth, W. Glenn McCluggage, Iain A. McNeish, Philippe Morice, Shibani Nicum, Ana Oaknin, José Alejandro Pérez Fidalgo, Sandro Pignata, Pedro T. Ramírez, Isabelle Ray‐Coquard, Ignacio Romero, Giovanni Scambia, Jalid Sehouli, Ronnie Shapira‐Frommer, Sudha Sundar, David S.P. Tan, Çağatay Taşkıran, Willemien J. van Driel, Ignace Vergote, François Planchamp, Cristiana Sessa, Anna Fagotti - Annals of Oncology 2024 cited by 284

  17. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial

    Authors: Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n, Patricia LoRusso, Jean-­Marc Ferrero, Tanja Badovinac-Črnjević, Silke Hoersch, Melanie C. Smitt, Hans Wildiers - The Lancet Oncology 2017 cited by 523

  18. openalex_id:w4226283539

    Authors: Susana Banerjee, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Eileen Holmes, Elizabeth Lowe, Paul DiSilvestro cited by 185

  19. The forefront of ovarian cancer therapy: update on PARP inhibitors

    Authors: Mansoor Raza Mirza, Robert L. Coleman, Antonio González-Martı́n, Kathleen N. Moore, Nicoletta Colombo, Isabelle Ray‐Coquard, Sandro Pignata - Annals of Oncology 2020 cited by 370

  20. Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results.

    Authors: Funda Meric‐Bernstam, Vicky Makker, Ana Oaknin, Do‐Youn Oh, Susana Banerjee, Antonio González-Martı́n, Kyung Hae Jung, Iwona Ługowska, Luís Manso, Aránzazu Manzano, Bohuslav Melichar, Salvatore Siena, Daniil Stroyakovskiy, Chiedozie Anoka, Yan Ma, Soham D. Puvvada, Jung‐Yun Lee - Journal of Clinical Oncology 2023 cited by 86

  21. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database

    Authors: Pierre‐Marie Morice, Alexandra Léary, Charles Dolladille, Basile Chrétien, Laurent Poulain, Antonio González-Martı́n, Kathleen N. Moore, Eileen M. O’Reilly, Isabelle Ray‐Coquard, Joachim Alexandre - The Lancet Haematology 2020 cited by 244

  22. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

    Authors: Ian E. Krop, Sung‐Bae Kim, Antonio González-Martı́n, Patricia LoRusso, Jean-­Marc Ferrero, Melanie C. Smitt, Ron Yu, Abraham C.F. Leung, Hans Wildiers - The Lancet Oncology 2014 cited by 716

  23. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer

    Authors: Nicoletta Colombo, Carien L. Creutzberg, Frédéric Amant, Tjalling Bosse, Antonio González-Martı́n, Jonathan A. Ledermann, Christian Marth, Remi A. Nout, Denis Querleu, Mansoor Raza Mirza, Cristiana Sessa - International Journal of Gynecological Cancer 2015 cited by 757

  24. Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials

    Authors: Bradley J. Monk, Takayuki Enomoto, W. Martin Kast, Mary McCormack, David S.P. Tan, Xiaohua Wu, Antonio González-Martı́n - Cancer Treatment Reviews 2022 cited by 130